PriceTargets.com logo

NASDAQ:SWAV - ShockWave Medical Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $203.00
  • Forecasted Upside: 0.00 %
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 4 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$202.99 As of 10/20/2021 01:00 AM ET
▲ +4.06 (2.04%)

This chart shows the closing price for SWAV by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New ShockWave Medical Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SWAV and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SWAV

Analyst Price Target is $203.00
▲ +0.00% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for ShockWave Medical in the last 3 months. The average price target is $203.00, with a high forecast of $220.00 and a low forecast of $189.00. The average price target represents a 0.00% upside from the last price of $202.99.

This chart shows the closing price for SWAV for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 7 contributing investment analysts is to hold stock in ShockWave Medical. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
4/28/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
7/27/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
10/25/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
1/23/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
4/23/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
7/22/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
9/20/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
10/20/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/10/2021Morgan StanleyBoost Price TargetEqual Weight$152.00 ➝ $200.00High
8/10/2021SVB LeerinkBoost Price TargetOutperform$208.00 ➝ $220.00High
7/15/2021SVB LeerinkInitiated CoverageOutperform$208.00High
7/12/2021Bank of AmericaDowngradeBuy ➝ Neutral$180.00 ➝ $200.00Low
6/18/2021Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$189.00Medium
6/15/2021Piper SandlerBoost Price TargetOverweight$165.00 ➝ $207.00Medium
6/7/2021Wells Fargo & CompanyBoost Price TargetOverweight$161.00 ➝ $189.00High
5/11/2021Morgan StanleyBoost Price TargetEqual Weight$145.00 ➝ $152.00High
5/11/2021Canaccord GenuityBoost Price TargetBuy$149.00 ➝ $202.00High
5/11/2021Wells Fargo & CompanyBoost Price TargetOverweight$151.00 ➝ $161.00High
5/11/2021Bank of AmericaUpgradeNeutral ➝ Buy$180.00High
5/11/2021Piper SandlerUpgradeNeutral ➝ Overweight$134.00 ➝ $165.00High
4/28/2021OppenheimerReiterated RatingHoldHigh
4/19/2021Morgan StanleyBoost Price TargetEqual Weight$130.00 ➝ $145.00Low
3/31/2021Canaccord GenuityBoost Price TargetBuy$147.00 ➝ $149.00Medium
2/25/2021Morgan StanleyBoost Price TargetEqual Weight$103.00 ➝ $130.00High
2/18/2021Piper SandlerBoost Price TargetNeutral$132.00 ➝ $134.00High
2/2/2021Canaccord GenuityBoost Price TargetBuy$87.00 ➝ $131.00Low
1/20/2021Piper SandlerDowngradeOverweight ➝ Neutral$96.00 ➝ $132.00High
1/12/2021Wells Fargo & CompanyBoost Price TargetOverweight$95.00 ➝ $134.00High
12/15/2020Morgan StanleyBoost Price TargetEqual Weight$89.00 ➝ $103.00Low
12/1/2020Bank of AmericaDowngradeBuy ➝ Neutral$105.00High
11/11/2020Morgan StanleyBoost Price TargetEqual Weight$72.00 ➝ $89.00Low
11/10/2020Wells Fargo & CompanyBoost Price TargetOverweight$90.00 ➝ $95.00High
11/10/2020Piper SandlerBoost Price TargetOverweight$86.00 ➝ $93.00High
10/19/2020Morgan StanleyBoost Price TargetEqual Weight$55.00 ➝ $72.00Medium
10/16/2020Canaccord GenuityBoost Price TargetBuy$60.00 ➝ $87.00High
10/16/2020Wells Fargo & CompanyBoost Price TargetOverweight$80.00 ➝ $90.00High
10/16/2020Piper SandlerBoost Price TargetOverweight$76.00 ➝ $86.00High
9/18/2020Wells Fargo & CompanyBoost Price TargetPositive ➝ Overweight$59.00 ➝ $80.00High
9/15/2020Piper SandlerBoost Price Target$58.00 ➝ $76.00Medium
8/12/2020Morgan StanleyBoost Price TargetEqual Weight$42.00 ➝ $55.00High
8/12/2020Piper SandlerBoost Price TargetOverweight$54.00 ➝ $58.00High
8/12/2020Canaccord GenuityBoost Price TargetBuy$53.00 ➝ $60.00Low
7/8/2020OppenheimerInitiated CoverageHoldHigh
6/11/2020OppenheimerUpgradeUnderperform ➝ Market PerformHigh
6/9/2020Canaccord GenuityBoost Price TargetBuy$46.00 ➝ $53.00Medium
6/9/2020Piper SandlerBoost Price TargetOverweight$45.00 ➝ $54.00High
5/13/2020Morgan StanleyBoost Price TargetEqual Weight$40.00 ➝ $42.00High
5/13/2020Canaccord GenuityReiterated RatingBuy$53.00 ➝ $46.00High
5/13/2020Wells Fargo & CompanyBoost Price TargetBuy$43.00 ➝ $46.00High
5/12/2020OppenheimerInitiated CoverageSell$23.00High
4/21/2020Piper SandlerLower Price TargetOverweight$54.00 ➝ $45.00High
4/1/2020OppenheimerDowngradeMarket Perform ➝ Underperform$23.00High
3/27/2020Morgan StanleyLower Price TargetEqual Weight$51.00 ➝ $40.00Medium
2/21/2020Bank of AmericaUpgradeNeutral ➝ Buy$47.00 ➝ $50.00High
2/14/2020Piper SandlerBoost Price Target$50.00 ➝ $54.00Low
1/23/2020Piper SandlerReiterated RatingBuy$48.00Low
12/17/2019Morgan StanleyBoost Price TargetEqual Weight$35.00 ➝ $47.00Low
12/12/2019Wells Fargo & CompanyUpgradeMarket Perform ➝ Overweight$49.00High
12/11/2019Piper Jaffray CompaniesBoost Price TargetOverweight$43.00 ➝ $46.00High
11/8/2019Canaccord GenuityLower Price TargetBuy$65.00 ➝ $49.00High
11/8/2019Piper Jaffray CompaniesBoost Price TargetOverweight$39.00 ➝ $43.00High
10/22/2019OppenheimerInitiated CoverageMarket PerformHigh
10/21/2019Piper Jaffray CompaniesInitiated CoverageOverweight$39.00High
6/18/2019Canaccord GenuityBoost Price TargetBuy ➝ Positive$50.00 ➝ $65.00Low
6/13/2019Bank of AmericaReiterated RatingNeutral$44.00Low
4/1/2019Wells Fargo & CompanyInitiated CoverageMarket Perform ➝ Market Perform$33.00Low
4/1/2019Bank of AmericaInitiated CoverageNeutral ➝ Neutral$37.00Low
4/1/2019Morgan StanleyInitiated CoverageEqual Weight ➝ Equal Weight$32.00Low
(Data available from 10/20/2016 forward)

News Sentiment Rating

0.56 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/24/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/23/2021
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/23/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/22/2021
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/22/2021
  • 9 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/21/2021
  • 4 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/20/2021
  • 6 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
10/20/2021

Current Sentiment

  • 6 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

ShockWave Medical logo
Shockwave Medical, Inc. operates as a medical device company, which focuses on developing and commercializing products intended to transform the way calcified cardiovascular disease is treated. The firm offers M5 catheters for treating above-the-knee peripheral artery disease; C2 catheters for treating coronary artery disease; and S4 catheters or treating below-the-knee peripheral artery disease. The company was founded by Daniel Hawkins, John M. Adams, and Todd J. Brinton on June 17, 2009 and is headquartered in Santa Clara, CA.
Read More

Today's Range

Now: $202.99
Low: $195.01
High: $203.06

50 Day Range

MA: $207.33
Low: $172.18
High: $235.57

52 Week Range

Now: $202.99
Low: $66.09
High: $237.76

Volume

150,174 shs

Average Volume

374,650 shs

Market Capitalization

$7.14 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.28

Frequently Asked Questions

What sell-side analysts currently cover shares of ShockWave Medical?

The following sell-side analysts have issued research reports on ShockWave Medical in the last twelve months: Bank of America Co., Canaccord Genuity, Morgan Stanley, Oppenheimer Holdings Inc., Piper Sandler, SVB Leerink LLC, Wells Fargo & Company, and Zacks Investment Research.
View the latest analyst ratings for SWAV.

What is the current price target for ShockWave Medical?

6 Wall Street analysts have set twelve-month price targets for ShockWave Medical in the last year. Their average twelve-month price target is $203.00, suggesting a possible upside of 0.4%. SVB Leerink LLC has the highest price target set, predicting SWAV will reach $220.00 in the next twelve months. Wells Fargo & Company has the lowest price target set, forecasting a price of $189.00 for ShockWave Medical in the next year.
View the latest price targets for SWAV.

What is the current consensus analyst rating for ShockWave Medical?

ShockWave Medical currently has 4 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in SWAV, but not buy more shares or sell existing shares.
View the latest ratings for SWAV.

What other companies compete with ShockWave Medical?

Other companies that are similar to ShockWave Medical include Fresenius SE & Co. KGaA, Insulet, Teleflex, Abiomed, NovoCure, Penumbra, Hill-Rom, Tandem Diabetes Care, Globus Medical, Inspire Medical Systems, Integra LifeSciences, ICU Medical, Inari Medical, Nevro and Merit Medical Systems.

How do I contact ShockWave Medical's investor relations team?

ShockWave Medical's physical mailing address is 5403 Betsy Ross Drive, Santa Clara CA, 95054. The company's listed phone number is (510) 279-4262 and its investor relations email address is [email protected] The official website for ShockWave Medical is www.shockwavemedical.com.